Exatecan

OSAKA, Japan and CAMBRIDGE, Mass. — September 22, 2026 Takeda announced that new data from its oncology pipeline and...

LONDON and PHILADELPHIA — September 16, 2026 Avacta Therapeutics announced clinical proof of mechanism for AVA6103, its next-generation controlled-release...

MELBOURNE, Australia & OXFORD, UK, Aug. 3, 2026 Aravax announced that the U.S. Food and Drug Administration (FDA) has...

SHANGHAI, China, July 27, 2026 IMPACT Therapeutics announced the nomination of IMP3201 as a preclinical candidate (PCC), marking the...

Marseille, France | July 21, 2026 Innate Pharma SA has announced the completion of enrollment in the dose-escalation portion...

SHANGHAI, China, July 2, 2026 Multitude Therapeutics Co., Ltd. announced encouraging interim Phase I clinical results for its CDH17-directed...